Tests fitusiran to prevent bleeds in people with severe hemophilia A

Trial details

Who runs it

Sanofi

Trial code

NCT06145373EU 2022-502414-84-00

Record updated

23 September 2026

Original description

This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.Read full original descriptionShow less

An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fitusiran Prophylaxis in Male Participants Aged ≥12 Years of Age With Severe Hemophilia A, With or Without Inhibitors

This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.

This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis.

Study details include:

* The study duration will be up to approximately 28 months:

* There will be an approximately 2-month screening period. * There will be an approximately 2-month period before fitusiran treatment starts (pre-fitusiran treatment period) * The fitusiran treatment duration will be up to 18-months (fitusiran treatment period) * The antithrombin (AT) follow-up (FU) period will be approximately 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%). * The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.

Inclusion: Male participants must be ≥12 years of age inclusive, at the time of signing the informed consent; Diagnosis of severe congenital hemophilia A (FVIII < 1%) as evidenced by a central laboratory measurement at screening or documented medical record evidence; Inhibitor titer of ≥0.6 BU/mL at Screening, or; Inhibitor titer of <0.6 BU/mL at Screening with medical record evidence of 2 consecutive titers ≥0.6 BU/mL, or; Inhibitor titer of <0.6 BU/mL at Screening with medical record evidence of anamnestic response; Participants who are currently on the full labeled dose of emicizumab prophylaxis, irrespective of inhibitor/non-inhibitor status; Signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion: Current or prior participation in a fitusiran trial; Current or prior participation in a gene therapy trial; Known coexisting bleeding disorders; History of antiphospholipid antibody syndrome; History of arterial or venous thromboembolism, atrial fibrillation, significant valvular disease, myocardial infarction, angina, transient ischemic attack, or stroke. Participants who have experienced thrombosis associated with indwelling venous access may be enrolled; Presence of clinically significant liver disease; Coexisting thrombophilic disorder - Hepatitis C virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis; Presence of acute hepatitis, ie, hepatitis A, hepatitis E; Presence of acute or chronic hepatitis B infection; AT activity <60% at Screening, as determined by central laboratory measurement; Known to be HIV positive with CD4 count <200 cells/μL; Participants are excluded from the study if any of the following criteria apply:; Reduced renal function; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

ClinicalTrials.gov NCT06145373 · EU CTIS 2022-502414-84-00